JP2005504086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504086A5 JP2005504086A5 JP2003530210A JP2003530210A JP2005504086A5 JP 2005504086 A5 JP2005504086 A5 JP 2005504086A5 JP 2003530210 A JP2003530210 A JP 2003530210A JP 2003530210 A JP2003530210 A JP 2003530210A JP 2005504086 A5 JP2005504086 A5 JP 2005504086A5
- Authority
- JP
- Japan
- Prior art keywords
- aag
- melting point
- composition
- protic solvent
- ansamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 54
- 238000000034 method Methods 0.000 claims 47
- 230000008018 melting Effects 0.000 claims 26
- 238000002844 melting Methods 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 24
- 239000003586 protic polar solvent Substances 0.000 claims 24
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 claims 16
- 229960000885 rifabutin Drugs 0.000 claims 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 10
- 238000002425 crystallisation Methods 0.000 claims 7
- 230000008025 crystallization Effects 0.000 claims 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 239000000010 aprotic solvent Substances 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 claims 2
- VSCUCHUDCLERMY-UHFFFAOYSA-N 2-ethoxybutane Chemical compound CCOC(C)CC VSCUCHUDCLERMY-UHFFFAOYSA-N 0.000 claims 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 238000005119 centrifugation Methods 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 230000008020 evaporation Effects 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32663901P | 2001-09-24 | 2001-09-24 | |
| US33189301P | 2001-11-21 | 2001-11-21 | |
| PCT/US2002/029715 WO2003026571A2 (en) | 2001-09-24 | 2002-09-18 | Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504086A JP2005504086A (ja) | 2005-02-10 |
| JP2005504086A5 true JP2005504086A5 (https=) | 2005-12-22 |
Family
ID=26985493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530210A Pending JP2005504086A (ja) | 2001-09-24 | 2002-09-18 | １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7579462B2 (https=) |
| EP (1) | EP1435939B1 (https=) |
| JP (1) | JP2005504086A (https=) |
| KR (1) | KR20040054692A (https=) |
| CN (1) | CN100378079C (https=) |
| AT (1) | ATE387198T1 (https=) |
| CA (1) | CA2460498A1 (https=) |
| DE (1) | DE60225307T2 (https=) |
| WO (1) | WO2003026571A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| CA2460498A1 (en) | 2001-09-24 | 2003-04-03 | Conforma Therapeutics Corporation | Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins |
| WO2003037860A2 (en) | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| WO2003066005A2 (en) | 2002-02-08 | 2003-08-14 | Conforma Therapeutics Corporation | Ansamycins having improved pharmacological and biological properties |
| MXPA06002997A (es) | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| AU2004309395C1 (en) | 2003-12-23 | 2012-10-04 | Infinity Discovery, Inc. | Analogs of benzoquinone-containing ansamycins for the treatment of cancer |
| KR101045324B1 (ko) * | 2004-08-11 | 2011-06-30 | 한국생명공학연구원 | 젤다나마이신 유도체 및 그 생합성 방법 |
| US7371906B2 (en) * | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| US20090130163A1 (en) * | 2005-02-18 | 2009-05-21 | Abraxis Bio Scoence, Inc. | Drugs With Improved Hydrophobicity For Incorporation in Medical Devices |
| AU2006230447A1 (en) | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
| BRPI0608661A2 (pt) * | 2005-04-07 | 2010-01-19 | Conforma Therapeutics Corp | formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica |
| US7648976B2 (en) * | 2005-11-23 | 2010-01-19 | Bristol-Myers Squibb Company | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| US20090042847A1 (en) * | 2005-11-23 | 2009-02-12 | Kosan Biosciences Incorporated | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| JP2009518302A (ja) * | 2005-12-01 | 2009-05-07 | コンフォーマ・セラピューティクス・コーポレイション | アンサマイシン含有組成物 |
| KR100796637B1 (ko) * | 2006-09-29 | 2008-01-22 | 한국생명공학연구원 | 젤다나마이신 유도체, 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 및치료제 |
| EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| KR100861697B1 (ko) * | 2007-01-30 | 2008-10-07 | 한국생명공학연구원 | Ａｈｂａ 생합성 유전자 변이주를 이용한 안사마이신유도체의 생산 방법 및 신규한 안사마이신 유도체 |
| KR20110090925A (ko) | 2008-10-15 | 2011-08-10 | 인피니티 파마슈티컬스, 인코포레이티드 | 안사마이신 하이드로퀴논 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3595955A (en) * | 1969-03-26 | 1971-07-27 | Upjohn Co | Geldanamycin and process for producing same |
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| CA2127457A1 (en) | 1992-01-06 | 1993-07-22 | Walter P. Cullen | Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone |
| US5387584A (en) | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
| JP2794342B2 (ja) * | 1993-06-29 | 1998-09-03 | ファイザー・インク． | 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体 |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5883236A (en) * | 1997-11-19 | 1999-03-16 | Abbott Laboratories | Process for N-desmethylating erythromycins and derivatives thereof |
| JP2002541255A (ja) | 1999-04-09 | 2002-12-03 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物 |
| CA2460498A1 (en) | 2001-09-24 | 2003-04-03 | Conforma Therapeutics Corporation | Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins |
| EP1923061A1 (en) | 2001-09-24 | 2008-05-21 | Conforma Therapeutic Corporation | Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins |
-
2002
- 2002-09-18 CA CA002460498A patent/CA2460498A1/en not_active Abandoned
- 2002-09-18 WO PCT/US2002/029715 patent/WO2003026571A2/en not_active Ceased
- 2002-09-18 AT AT02761732T patent/ATE387198T1/de not_active IP Right Cessation
- 2002-09-18 KR KR10-2004-7004202A patent/KR20040054692A/ko not_active Ceased
- 2002-09-18 DE DE60225307T patent/DE60225307T2/de not_active Expired - Lifetime
- 2002-09-18 JP JP2003530210A patent/JP2005504086A/ja active Pending
- 2002-09-18 EP EP02761732A patent/EP1435939B1/en not_active Expired - Lifetime
- 2002-09-18 CN CNB028187180A patent/CN100378079C/zh not_active Expired - Fee Related
- 2002-09-18 US US10/490,785 patent/US7579462B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005504086A5 (https=) | ||
| JP5455916B2 (ja) | ３−イソチアゾリノン誘導体およびその中間体生成物を連続的に生産する方法 | |
| EP2595976A1 (fr) | Procede de preparation de derives d'amino-benzoyl-benzofurane | |
| JP2002535307A (ja) | 結晶１α−ヒドロキシビタミンＤ２とその精製方法 | |
| JP2003528094A5 (https=) | ||
| HUE029282T2 (en) | Methods for the preparation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and its precursors | |
| US20070117992A1 (en) | Crystalline citalopram diol intermediate alkali | |
| JP2009542625A (ja) | 高純度スクラロースの改良製造法 | |
| HUE028377T2 (en) | Method for cleaning mesotrione | |
| JP2006521340A5 (https=) | ||
| EP2358729A1 (fr) | Pentasaccharide cristallise, son procede d'obtention et son utilisation pour la preparation d'idraparinux | |
| CN109689620B (zh) | 拆分巴氯芬盐的方法 | |
| JP4205130B2 (ja) | トレミフェン結晶化法 | |
| JP4080545B2 (ja) | （ｓ）−ｎ，ｎ′−ビス［２−ヒドロキシ−１−（ヒドロキシメチル）エチル］−５−［（２−ヒドロキシ−１−オキソプロピル）アミノ］−２，４，６−トリヨード−１，３−ベンゼンジカルボキシアミドを直鎖状または分岐状の（ｃ５〜ｃ６）アルコールまたはそれらの混合物から結晶化させる方法 | |
| MXPA02005330A (es) | Procedimiento para la preparacion de hidrocloruro de epinastina en la modificacion cristalina de alto punto de fusion. | |
| JP5828594B2 (ja) | 溶融ピロロカルバゾール誘導体を精製するための方法 | |
| JP4397990B2 (ja) | ３−アルキルフラバノノール誘導体の精製法 | |
| CN116209654B (zh) | 纯化维兰特罗三苯乙酸盐的方法 | |
| WO2010031953A1 (fr) | Procede de preparation du 1,6:2,3-dianhydro-beta-d-mannopyranose | |
| RU99113024A (ru) | СПОСОБ ОЧИСТКИ СЛОЖНЫХ ЭФИРОВ КАРБАЗОЛА-ПРЕДШЕСТВЕННИКОВ 6-ХЛОР-α-МЕТИЛ-КАРБАЗОЛ-2-УКСУСНОЙ КИСЛОТЫ | |
| US20060167280A1 (en) | Method for purifying simvastatin | |
| JP2004292364A (ja) | 塩酸エピナスチンの製造方法 | |
| JP4694018B2 (ja) | メバロラクトンメタクリル酸エステルの精製方法 | |
| JP2007521224A (ja) | Ｒａｃ−ビカルタミドの精製及び単離方法 | |
| CN107674046B (zh) | 一种阿扎那韦环氧化物中间体的纯化方法 |